

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 7/01, A61K 39/40, C07K 16/12 // 19/00		A1	(11) International Publication Number: WO 97/29185 (43) International Publication Date: 14 August 1997 (14.08.97)
(21) International Application Number: PCT/SE97/00172		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 5 February 1997 (05.02.97)			
(30) Priority Data: 9600434-6 6 February 1996 (06.02.96) SE			
(71)(72) Applicant and Inventor: MÅRDH, Sven [SE/SE]; Sjölidens 13, S-590 77 Vreta Kloster (SE).			
(74) Agent: GÖTEBORGS PATENTBYRÅ AB; P.O. Box 5005, S-402 21 Göteborg (SE).		Published <i>With international search report.</i>	
(54) Title: RECOMBINANT PHAGES			
(57) Abstract			
<p>The present invention relates to bacteriophages for use in the treatment or prophylaxis of bacterial infections, especially mucosal bacterial infections such as <i>Helicobacter pylori</i> infections. In particular, it relates to modified filamentous bacteriophages, e.g. M13 phages, for such use, which bacteriophages present at its surface a recombinant protein comprising: (i) a first component derived from a bacteriophage surface protein; and (ii) a second component comprising variable region sequences of an antibody to provide a bacterial antigen binding site, said second component rendering said bacteriophage capable of binding to and thereby inhibiting growth of bacterial cells involved in the etiology of said infection.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

RECOMBINANT PHAGES

TECHNICAL FIELD

- 5 This invention relates to bacteriophages useful for the treatment of bacterial infections, especially mucosal bacterial infections such as *Helicobacter pylori* infections.

10 BACKGROUND ART

Bacteriophages and antibiotic resistance

15 Resistance to antibiotics is a global problem of increasing medical and economical importance. There is thus a great need for alternative methods to eradicate bacteria which will circumvent the problem of such resistance.

20 A bacteriophage, or phage, is a virus which specifically infects bacteria. Phages bind to their host bacterium and transfer genes encoding various phage proteins. They utilize the protein-synthesizing machinery, amino acids etc., and the energy provided by the host bacterium for their replication (Maloy et al. (eds.): Microbial genetics. Jones and Bartlett Publishers, 1994).

25 Most phages lyse or by other mechanisms destroy specific strains of bacteria. The present invention stems from the realisation that genetic modification of phages, in particular filamentous bacteriophages, offers a means for designing new bacterium-specific phages capable of eradicating certain bacteria, e.g. *Helicobacter pylori*, and having the potential to overcome problems related to antibiotic resistance.

Filamentous phages

E. coli cells bearing hair-like F-pili are hosts for filamentous phages such as M13, fd and f1. These Ff (F pili, filamentous) phages are nearly identical in sequence and behaviour (Rashed & Oberer (1986) Microbiological reviews 50, 401-427; Kornberg & Baker, in: DNA Replication, p. 557-570, W.H. Freeman and Co., New York 1992). Ff phages alone among the bacterial viruses do not produce a lytic infection, but rather induce a state in which the infected host cells produce and secrete phage particles without undergoing lysis.

10

The single-stranded genome of phage M13 encodes 10 different proteins. The DNA is enclosed in a protein coat comprised of approximately 2700 copies of the gene 8 protein (g8p). A viable M13 phage also expresses five copies of the 43 kDa gene 3 protein (g3p) on its tip, which protein is responsible for adsorption to *E. coli* pili. The gene 3 protein is anchored to the virus coat via the C-terminal part of the polypeptide chain, whereas the N-terminal globular domain is exposed and mediates the attachment of the phage to the tip of a host F pilus. By electron microscopy, the adsorption complex appears as a "knob-on-stem" structure at one end of the phage. During infection, the leader sequences of g3p and g8p direct the transport of these proteins into the inner membrane of the bacterial cell.

20

The Ff phages have gained popularity as cloning vectors because they have no physical constraints limiting the length of DNA that can be packaged and because they allow the easy purification of single-stranded DNA. A *phagemid* is a vector which carries both the M13 (single-stranded) and plasmid (double-stranded) origins of replication. Phagemids can be grown as plasmids or packaged as recombinant M13 phage with the aid of a helper phage such as M13K07 (Veira & Messing (1987) Methods in Enzymol. 153, 3-11).

Recombinant antibody production

- Antibody molecules contain discrete fragments which can be isolated by protease digestion or produced by recombinant techniques. One such fragment is the Fv (fragment variable) which is composed only of the V_L and V_H regions of the antibody. In US 4,946,778 a recombinant version of the Fv fragment, designated single-chain Fv (ScFv), is described, where the two variable regions are artificially joined with a neutral linker and expressed as a single polypeptide chain.
- A technology for recombinant antibody production has been developed by McCafferty and coworkers (McCafferty (1990) *Nature* 348, 552-554; Winter & Milstein (1991) *Nature* 349, 293). This approach relies on a phage-display system in which V_H (variable heavy) and V_L (variable light) genes are cloned into a phage vector whereafter fragments of antibodies are expressed as fusion proteins displayed on the phage surface. With this approach, antibodies of defined specificity and affinity can be selected from a population. It has been suggested that antibodies isolated and manufactured in prokaryotic systems should be called "coliclonal" antibodies (Chiswell & McCafferty (1992) *Trends in Biotechnology* 10, 80-84).
- The commercially available phagemid pCANTAB5 is designed such that antibody variable region genes can be cloned between the leader sequence and the main body of the M13 gene 3. The g3p leader sequence directs transport of the resulting fusion protein to the inner membrane and/or periplasm of *E. coli* where the main g3p domain attaches the fusion protein to the tip of the assembling phage. The expression of the antibody-g3p gene is controlled by an inducible lac promoter on the phagemid.

Helicobacter pylori infection

It is widely accepted that the bacterium *Helicobacter pylori* is the main cause of gastric and duodenal ulcer, responsible for 84% and 95%, respectively, of reported cases (Kuipers, E.L. et al. (1995) *Aliment. Pharmacol. Ther.* 9 (suppl.2), 59-69). *H. pylori* colonises the wall of the stomach, protected from the acid environment by a layer of mucus which lines the stomach wall, and by a metabolic process which enables the organism to secrete ammonia to neutralise acid.

- 10 Conventional antibiotic treatment appears to have little effect on *H. pylori*. This is probably due to: (i) poor access of the antimicrobial agent to the organism which is not directly exposed to the blood circulation; and (ii) rapid passage of many oral antibiotics through the stomach, or degradation of such antibiotics in the acid conditions of the stomach.

15

PURPOSE OF THE INVENTION

- 20 The purpose of the present invention is to provide new forms of treatment for eradication of bacteria, especially eradication of bacteria responsible for mucosal bacterial infections such as *Helicobacter pylori*. In particular, it provides filamentous bacteriophages genetically modified to have binding specificity towards another bacterial host for use in therapy.

- 25 Methods of treatment of mucosal bacterial infections based on recombinant phages are believed to be superior to conventional antibiotic treatment for several reasons, e.g. the following:

- it will be possible to eradicate bacteria resistant to conventional antibiotics;
- the high specificity of the recombinant phage towards specific bacterial species;
- propagation of the phage is self-limiting;

30

- in the case of *Helicobacter pylori* infections, the motility of *Helicobacter pylori* could help to distribute the phage to all parts of the gastric mucosa.

5 DISCLOSURE OF THE INVENTION

In the present description and examples, the terms "standard protocols" and "standard procedures" are to be understood as protocols and procedures found in an ordinary laboratory manual such as: Sambrook, J., Fritsch, E.F. and Maniatis, T. 10 (1989) Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

In a first aspect, this invention provides a modified bacteriophage for use in the treatment or prophylaxis of a bacterial infection, which bacteriophage presents at 15 its surface a recombinant protein comprising
(i) a first component derived from a bacteriophage surface protein; and
(ii) a second component comprising variable region sequences of an antibody to provide a bacterial antigen binding site, said second component rendering said bacteriophage capable of binding to and thereby inhibiting growth of bacterial 20 cells involved in the etiology of said infection.

The said modified bacteriophage can e.g. be a modified filamentous phage, such as a modified M13 phage.

25 The said bacterial infection can e.g. be a mucosal bacterial infection such as *Helicobacter pylori* infection. However, the present invention is not restricted to phages capable of incapacitating *Helicobacter pylori* cells, but rather comprises phages with altered properties which can be used for incapacitating a wide range of bacteria. It will be understood that a phage according to the invention which is 30 specific for any bacterial species can be prepared by the skilled person on the basis

of the present disclosure. Phages according to the invention are suitable for treatment of any mucosal bacterial infection accessible to the outside world. Examples of such mucosal epithelia are nasal, lung, gastrointestinal tract, urinary bladder and vagina.

5

Examples of other bacterial infections which could be treated with phages according to the invention are:

- infections in the urinary tract by *E. coli*, *Staphylococcus saprophyticus*, *Klebsiella spp*, *Proteus spp* or *Pseudomonas aeruginosa*;
- 10 • vaginal infections by *Clamydia*;
- nose/toncillar/lung infections by *Streptoccus*, *Staphylococcus*, *Haemophilus influenza*, *Pneumococcus* or *Mycoplasma pneumoniae*;
- infections in the gastrointestinal tract by *Salmonella*, *Shigella*, *Yersinia*, *Campylobacter jejuni*, *Campylobacter coli*, *Helicobacter*, *Vibrio cholera* or *E. coli*.

15

The said first component of the recombinant protein mentioned above can preferably be derived from the protein responsible for adsorption of the unmodified form of said bacteriophage to bacterial pili, e.g. the g3p protein from a M13 phage.

20

The said second component of said recombinant protein can e.g. comprise a recombinant single-chain Fv (ScFv) polypeptide. Consequently, the said recombinant protein can e.g. be a g3p – ScFv fusion protein.

25

- In a preferred form, the bacteriophage according to the invention is a bacteriophage for use in the treatment or prophylaxis of *Helicobacter pylori* infection wherein the antibody variable region sequences of said recombinant polypeptide are variable region sequences of a monoclonal antibody selected from the monoclonal antibodies of hybridoma cell lines 5F8 (ECACC No.95121524),
30 2H6 (ECACC No.95121526) and 5D8 (ECACC No.95121527).

Thus, the bacteriophage according to the invention can e.g. be the modified M13 bacteriophage designated B8 deposited at the NCIMB under accession number NCIMB 40779, or a derivative thereof which retains the ability to bind and infect
5 *Helicobacter pylori*.

Phages with the desired properties can be obtained by e.g. one of the following methods:

- 10 (a) Screening naturally occurring phages, or phage libraries containing phages expressing a multitude of variable antibody fragments. Phage libraries may be obtained e.g. from immune cells, from a large number of individuals. Due to the vast genetic variability, such large phage libraries are likely to comprise the desired, specific phage directed towards bacteria, to which the individuals previously have been exposed.
- 15 (b) Development of mutations in existing phages. Mutations occur in all living organisms including phages. The frequency of mutations may be increased, e.g. by chemical means or by means of short wavelength electromagnetic irradiation.
- 20 (c) Directed genetic modification of one or more amino acids, or other modifications of e.g. carbohydrate or lipid components, of the binding region of the phage, in order to increase the desired properties of the natural or recombinant phage. An example of this approach is further described in the experimental section. A bacteriophage according to the invention can thus be produced by a method comprising (a) isolating an antibody against a bacterial cell; (b) isolating the DNA encoding for a variable region of the heavy and light chains of the said antibody; and (c) introducing the said DNA into phage DNA so that the said antibody regions will be expressed on the surface of the phage.

In another aspect, the invention provides a pharmaceutical composition comprising a bacteriophage according to the invention in admixture with a pharmaceutically acceptable carrier or excipient.

5 Examples of suitable means of administration of phages according to the invention include:

- spray for nasal and lung applications;
- pre-treatment with omeprazole followed by phages suspended in bicarbonate buffers for the treatment of gastrointestinal mucosae;
- 10 • mixtures of muco-adhesive gels (i.e. cellulose-based gels, polycarbophil, poloxamer etc.) for the gastric mucosa and vaginal mucosa;
- bicarbonate buffers for use in the urinary bladder.

The number of phages to be administered can be determined by the skilled

15 person. Depending on the type of infection, the number of phages to be administered can range from 10^4 to 10^{10} .

In yet another aspect, the invention provides a method for treatment of a bacterial

infection in a mammal which comprises administering a bacteriophage or

20 pharmaceutical composition according to the invention. The said bacterial infections can e.g. be mucosal bacterial infections such as *Helicobacter pylori* infections. Included in the invention is also the use of a bacteriophage according to the invention in the manufacture of a medicament for the treatment or prophylaxis of a mucosal bacterial infection, e.g. *Helicobacter pylori* infections.

25

Further aspects of the invention are a hybridoma selected from 5F8 (ECACC No.95121524), 2H6 (ECACC No.95121526) and 5D8 (ECACC No.95121527), as well as a monoclonal antibody selected from the monoclonal antibodies produced by the said hybridomas. Hybridoma technology, in which antibody-producing B-cells from immunized animals are fused with myeloma cells, and resulting

hybridoma cell lines producing the desired antibody are selected, is well known in the art.

5 EXAMPLES

EXAMPLE 1: Production of monoclonal antibodies against *H. pylori*

1.1. *Antigen preparation*

10

H. pylori strains 17874, 25, 66, 253, and 1139 (obtained from Astra Hässle, Sweden) were cultured on columbia agar supplemented with 8.5% horse blood, 10% horse serum, 1% isovitalex under microaerophilic condition with Anaerocult C at +37°C.

- 15 Procedures described by Ma J-Y et al. (1994) Scand. J. Gastroenterol. 29, 961-965, were followed to prepare surface protein of *H. pylori*. Briefly, a total of 4 g of the five strains of *H. pylori* were incubated for 15 min at room temperature in 100 ml of 0.2 M glycine-HCl (pH 2.2). The pH was neutralized with 1 M NaOH. The antigen preparation was centrifuged at 10,000 × g for 10 min at +4°C. The pellet
20 was discarded and the supernatant was dialysed overnight against distilled water at +4°C and further used as "*H. pylori* antigen preparation" or "*H. pylori* surface proteins".

1.2. *Production of monoclonal antibody*

25

- Immunization procedure was carried out essentially as described by Cabero, J.L. et al. (1992) Acta Physiol. Scand. 144, 369-378. In brief, 2 mg/ml of surface protein of *H. pylori* was emulsified with an equal volume of Freund's complete adjuvant at +4°C. Two female DBA/1 mice were injected into the hind footpads with single
30 dose of 50 µl of antigen emulsion. 11 days after immunization, lymphocytes from

popliteal lymph nodes were fused with mouse myeloma cells (sp2 line) by using 50% (w/w) PEG 4000. The cell fusion suspension was then distributed in five microtiter plates. All cells were grown in DMEM culture medium containing 10% fetal calf serum plus 50 µg/ml gentamycin.

5

1.3. Enzyme-linked immunosorbent assay (ELISA)

Immunoplates were coated with 50 µl of 0.05 M Na₂CO₃/NaHCO₃ buffer, pH 9.8 containing indicated antigen (10 µg/ml) and incubated overnight at +4°C. Free 10 binding sites were blocked with PBS containing 0.05% Tween-20 (PBS-T) at +37°C for 1 hour. Primary antibody supernatant was added and incubated at +37°C for 1 hour. Goat anti-mouse IgG peroxidase conjugate was used as a secondary antibody. Bound peroxidase was detected with 0.04% (w/v) OPD and 14 mM hydrogen peroxide in 0.1 M citric acid/0.2 M NaHPO₄, pH 5. The plates were read 15 at 492 nm after stopping reaction by adding 2 M H₂SO₄. Washing with PBS-T was performed three times between each incubation.

1.4. Initial screening

20 From the fusion of lymph node cells and myeloma cells, 45 hybridoma clones were positive against *H. pylori* surface proteins by ELISA. 8 of them distinctly stained *H. pylori* taken from agar plate culture by means of immunohistochemistry. Hybridoma clones designated 2H6 (ECACC No. 95121526), 5D8 (ECACC No. 95121527), and 5F8 (ECACC No. 95121524) gave a 25 stronger reaction against *H. pylori* than others and were chosen for further studies.

EXAMPLE 2: Production of recombinant M13 phage against *H. pylori*

2.1. *Materials*

- 5 QuickPrep mRNA purification kit™, Mouse ScFv Module kit™, Expression
Module kit™, Detection Module Kit™, *Sfi*I, *Not*I, T4 DNA ligase and Anti-M13
sheep antibody were obtained from Pharmacia Biotech (Uppsala, Sweden). dNTPs
mix, 10 × PCR buffer and AmpliTaq DNA polymerase were purchased from
Perkin Elmer. Bacto-yeast extract, Bacto-tryptone, Bacto agar was purchased from
10 Difco Laboratories (Detroit, Michigan USA). Columbia agar plates and brucella
broth were obtained from Department of Microbiology (Linköping University,
Sweden). Anaerocult® C was obtained from Merck (Germany). SlowFade™
antifade kit was obtained from Molecular Probes Inc. (U.S.A.).

15 2.2. *Construction of phage antibody library*

The Recombinant Phage Antibody System™ (Pharmacia) was used to express
fragments of antibodies as fusion proteins displayed on the phage surface.

- 20 Total mRNA was isolated from hybridoma cell lines (2H6, 5D8, and 5F8) and
purified by affinity chromatography on oligo(dT)-cellulose, using QuickPrep
mRNA Purification Kit™ (Pharmacia).

The following steps were performed using the Mouse ScFv Module Kit™:

25

- First-strand cDNA was synthesized from hybridoma mRNA by using reverse
transcriptase and primer mixes provided with the Mouse ScFv Module
Kit™.

- cDNA corresponding to the variable regions of the heavy and light chains of mAbs was amplified with different primers (V_H and V_L chain primers, provided with the kit) by means of polymerase chain reaction (PCR). The V_H and V_L chains were analyzed by electrophoresis on a 1.5% agarose gel. Single bands at the correct size for V_H (340 bp) and V_L (325 bp) chain were obtained.
- The amplified V_H and V_L chains were purified and isolated by electrophoresis on a 1% agarose gel and were then assembled into a single-chain Fv (ScFv) gene using a DNA linker fragment provided with the kit. The linker fragment was constructed such that one end annealed to the 3'-end of the heavy chain while the other end hybridized with the 5'-end of the light chain. A single band at correct size for a ScFv gene (750 bp) was observed after electrophoresis.

15

- The assembled antibody ScFv DNA fragment was amplified with a set of oligonucleotide primers (provided with the kit) that introduced *NotI* and *SfiI* restriction sites. The fragment was purified on a spun column (provided with the kit) to remove linkers, dNTPs and Taq DNA polymerase. The ScFv fragment was digested with *NotI* and *SfiI* to generate cohesive ends for ligation to the pCANTAB5 vector.

The following steps were performed using the Expression Module Kit™:

- The ScFv fragment was ligated to the phagemid vector pCANTAB5 (provided with the kit), previously digested with *NotI* and *SfiI* to generate cohesive ends. T4 DNA ligase was used to join the ends of the fragment with corresponding ends of the phagemid. The ScFv fragment was then oriented in the proper direction, adjacent to and in frame with the M13 gene 3, for expression of the ScFv-g3p fusion protein.

- *E. coli* TG1 cells (provided with the kit) were made competent and transformed with the recombinant phagemid, containing a *lac* promoter and an ampicillin resistance marker. The transformed cells were grown at +30°C in a medium containing glucose and ampicillin. 3.2×10^4 ScFv clones were obtained. Ampicillin resistant colonies were scraped into medium to generate a library stock.
- Ampicillin resistant cells were infected with the helper phage M13K07 (provided with the kit), containing a kanamycin resistance marker, and grown in a glucose-deficient medium containing ampicillin and kanamycin. In the absence of glucose, the *lac* promotor present on the phagemid was no longer repressed. Phage particles displaying recombinant antibody fragments on their tips were produced and released from the cells.
- Phage-displayed antibodies capable of binding *H. pylori* antigen were selected by panning against the antigen. A culture flask was coated with 5 ml of *H. pylori* surface protein (15 µg/ml in 50 mM sodium carbonate buffer, pH 9.6) overnight. After three washes with PBS, the flask containing 10 ml of 1% BSA (w/v) in PBS was incubated at +37°C for 1 h. Following three washes with PBS, the flask was incubated at +37°C for 2 h in phage supernatant (medium containing phage). The flask was then washed 20 times with PBS containing 0.1% (w/v) Tween-20 and 20 times with PBS. Bound phage particles were then eluted by adding 1 ml of 100 mM triethylamine with gentle shaking for 10 min and immediately neutralized with 0.5 ml of 1 M Tris-HCl, pH 7.4.

The eluted phage was used to infect log-phase *E. coli* TG1 cells on the SOBAG agar containing 2% Bacto-tryptone, 0.5% Bacto-yeast extract, 0.05% NaCl, 0.01 M

MgCl₂, 0.01% glucose and 0.01% ampicillin. Colonies were picked, transferred, grown and rescued again with M13K07.

After the first round of selection by counting 100 clones, 6% of clones from the 5 microtiter plate rescue were positive against antigen preparation of *H. pylori* in an ELISA. In a third round of selection from the microtiter plate rescue, 95% of phage antibodies from individual clones reacted with the *H. pylori* antigens.

In a phage ELISA using the *H. pylori* antigen preparation as antigen, the 10 recombinant phage B8 has a titre 10-fold higher than the helper phage (wide phage). Phage B8 (NCIMB No. 40779) was chosen for further analysis.

EXAMPLE 3: ELISA

15

The phage-displayed recombinant antibodies were detected and identified in an enzyme-linked immunosorbent assay (ELISA), using the Detection Module Kit™.

A 96-well micro titre plate was coated with 200 µl of *H. pylori* antigen (10 µg/ml in 20 50 mM Na₂CO₃/NaHCO₃, pH 9.6) and incubated overnight at +4°C. The wells were washed with PBS containing 0.05% Tween 20 (PBS-T) for three times and then blocked with 300 µl of PBS containing 1% BSA for 1 hour at +37°C. Recombinant phage antibodies were diluted with an equal volume of 1% BSA/PBS and incubated for 20 min at room temperature. After washing, 5x10¹⁰ 25 phage transducing units were added (200 µl/well) and incubated for 2 hours at +37°C.

The wells were washed with PBS-T three times and then HRP/Anti M13 conjugate supplied in the Detection Module kit, diluted 1:5000 in 1% BSA/PBS 30 was added and incubated for 1 hour at +37°C. The wells were washed for three

times with PBS-T and then 2'2'-Azino-Bis(3-Ethylbenzthiazoline-6-Sulfonic Acid) Diammonium (ABTS) and H₂O₂ was added as peroxidase substrate and incubated at room temperature for 30 min. The absorbance was read at 405 nm using a computerized ELISA reader. Ovalbumin (10 µg/ml in PBS) was used as control antigen. Helper phage was used as a negative control. The results verified that the recombinant phage B8 specifically bound to the *H. pylori* surface antigen.

EXAMPLE 4: Immunoblotting

Proteins of *H. pylori* antigen preparation were separated by means of polyacrylamide gel electrophoresis in SDS-PAGE (10 µg proteins/well) and were then transferred to the nitrocellulose paper in a mini trans-blot electrophoretic transfer cell (BioRad, Richmond, CA, USA). The nitrocellulose paper was blocked with 10% BSA in PBS containing 0.1% Tween 20 for 1 h at room temperature with gentle shaking. Phage B8 (10¹¹ transducing units/ml) was then added and incubated together with the nitrocellulose paper overnight during gentle shaking at +4°C. Omission of primary antibody was used as a negative control. After washing with PBS-0.1% Tween 20, the nitrocellulose paper was incubated with HRP/anti-M13 conjugate (1:5000 dilution in blocking buffer) for 1 hour with shaking. Detection of binding was carried out by using ECL Detection Kit (Amersham, UK).

After staining the nitrocellulose paper with amido black, the major bands corresponded to proteins of 64 kDa, 36 kDa, 31 kDa and 27 kDa. Pooled MAbs (2H6, 5D8, and 5F8 corresponding to the hybridomas used for phage construction) reacted with the bands of 32 kDa and 64 kDa. A similar staining was obtained by immunoblotting with phage antibody B8. This result indicated that the genes of the variable heavy and light chains corresponding to the *H. pylori* specific monoclonal antibodies were correctly expressed on the phage.

EXAMPLE 5: Effects of recombinant phage on bacteria

In the following experiments, bacteria were cultured at +37°C in Brucella broth
5 containing 5% fetal calf serum in an atmosphere containing 10% CO₂ and 5% O₂.

The experiment was started ("Time 0") when 20 µl from the bacterial stock was mixed with 10 ml broth. CFU (colony forming units) per ml culture was determined at the indicated time points by diluting aliquots of the cultures in PBS
10 and spreading the dilutions on agar plates. The plates were incubated for two days at +37°C and the number of colonies of each plate was counted.

5.1. Time-dependent effect

- 15 The time-dependent effect of the recombinant phage B8 on growth of *H. pylori* strain 17874 was investigated by measuring CFU for three days with or without phage (Table 1). 10⁶ phages were added ("+ Phage") to 10 ml medium at Time 0. In the control ("– Phage") no phages were added.
- 20 After 3 days, CFU had increased about 5 orders of magnitude in the absence of the recombinant phage. After one day in presence of the phage, there was a drop of CFU by about one order of magnitude and the broth culture changed appearance from a turbid to a less turbid solution.

25 5.2. Effect on various bacterial strains

H. pylori laboratory strains 17874, 1139 and 244, together with *Staphylococcus aureus*, ATCC 29213, and *E. coli* TG1 were cultured with or without phage (10⁶ phages to 10 ml medium) for 24 h. CFU was analyzed at Time 0 and at 24 h (Table
30 2). The recombinant phage decreased CFU of the three *H. pylori* strains tested but

did not affect *Staphylococcus* or *E. coli*. *H. pylori* 17874 was not affected by the helper phage M13K07 used as a control

5.3. Effect on *H. pylori* strains

5

In a second experiment (Table 3), *H. pylori* strains 17874, 1139, 253, 25 and 66 were tested together with *Streptococcus* (Raf M87). Without phage, CFU increased during the 24 h incubation in all the bacteria tested. However, in culture with the recombinant phage present (10^6 phages to 10 ml medium at Time 0), the CFU values of the *H. pylori* strains 17874, 1139 and 25 were reduced in number and the growth rate of strains 253 and 66 were strongly reduced compared to the controls. Thus all *H. pylori* strains tested were affected by the phages.

15 EXAMPLE 6: Immunofluorescent staining of *H. pylori*

Phage antibody B8 was concentrated by PEG precipitation and immunofluorescent staining was performed on the *H. pylori* (17874 strain) taken from culture.

20

The following stock reagents were prepared to perform immunofluorescent staining:

Reagent A: 10^{12} transducing units/ml of phage antibodies was diluted 1:1 with 1% BSA/PBS;

25 Reagent B: sheep anti-M13 IgG diluted with 1% BSA/PBS;

Reagent C: anti-sheep IgFITC conjugate dilute 1:100 in 1% BSA/PBS;

Reagent D: 1 mg (w/v) of pronase in PBS.

30 Three days after culture, *H. pylori* (5 different strains), *Staphylococcus aureus* (ATCC 29213), and *Streptococcus* (Raf M 87) were separately suspended in PBS containing

1% BSA. 20 µl of each bacteria suspension were added onto glass slides. The bacteria were air dried and fixed in neutral formalin for 2 min, then washed by dipping slides six times into water and air dried at room temperature. Brief treatment in reagent D increased signal-to-noise ratio when sample slides were compared with controls. The slides were consecutively incubated with 30 µl of reagents A, B and C, for 30 min each, and washed in PBS between incubations. The slides were air dried and 1 drop of SlowFade was added before covering. All incubations were performed at room temperature. Negative control was performed by omitting the primary antibody.

10

The results showed that *H. pylori* was positively stained with phage antibody. The results indicate a good agreement with the CFU values obtained from culture experiments. Thus the expression of a specific antigen on the surface of the bacteria appears to be a prerequisite for execution of the biological effect by phage B8.

15

DEPOSIT OF BIOLOGICAL MATERIAL

20 The following hybridoma clones have been deposited under the Budapest Treaty at the European Collection of Animal Cell Cultures (ECACC), Salisbury, Wiltshire, U.K., on 15 December 1995:

- 2H6 (ECACC No. 95121526)
5D8 (ECACC No. 95121527)
25 5F8 (ECACC No. 95121524)

The recombinant phage B8 has been deposited under the Budapest Treaty at the National Collections of Industrial and Marine Bacteria (NCIMB), Aberdeen, Scotland, on 20 December 1995 with accession number NCIMB 40779.

TABLE 1

	- Phage	+ Phage B8
	CFU/ml	
Time 0	5×10^4	4×10^4
24 h.	1.9×10^7	8×10^3
48 h.	1.75×10^6	9.5×10^3
72 h.	4×10^8	3×10^6

TABLE 2

	<i>H. pylori</i>			<i>Staph.</i>	<i>E. coli</i>
	17874	1139	244		
	CFU/ml				
No phage	0 h.	2.1×10^4	4.7×10^4	10^4	7.8×10^7
	24 h.	5.8×10^6	1.5×10^7	3.1×10^6	10^{10}
Phage B8	0 h.	2.8×10^4	4.3×10^4	10^4	2.1×10^8
	24 h.	4×10^2	10^2	10^3	8×10^9
Phage M13K07	0 h.	3.9×10^4	(not determined)		
	24 h.	4×10^6	(not determined)		

TABLE 3

	- Phage		+ Phage B8	
	0 h.	24 h.	0 h.	24 h.
17874	1.5×10^4	5×10^6	1.3×10^4	2×10^2
1139	10^4	7×10^6	9×10^3	1.1×10^3
253	1.1×10^4	1.7×10^7	1.3×10^4	4×10^5
25	1.4×10^4	9×10^7	7×10^3	3×10^2
66	1.4×10^4	2.1×10^7	1.4×10^4	4×10^4
<i>Strept.</i>	2.3×10^7	5.6×10^7	1.9×10^7	5.8×10^7

21.

Applicant's or agent's file reference number	International application?
--	----------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>7</u> , line <u>3</u>	
B. IDENTIFICATION OF DEPOSIT	
Name of depositary institution <input checked="" type="checkbox"/> Further deposits are identified on an additional sheet	
The National Collections of Industrial and Marine Bacteria (NCIMB)	
Address of depositary institution (including postal code and country) 23 St. Machar Drive Aberdeen AB2 1RY Scotland, UK	
Date of deposit	Accession Number
20 December 1995	NCIMB 40779
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited biological material be made available only by issue thererof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions <i>mutatis mutandis</i> for any other designated state.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only

This sheet was received with the international application

Authorized officer

Linda McLean

For International Bureau use only

This sheet was received by the International Bureau on:

Authorized officer

22.

Applicant's or agent's file reference number	International application
--	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>6</u> , line <u>29</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution: The European Collection of Animal Cell Cultures (ECACC)	
Address of depositary institution (including postal code and country) ECACC, CAMR Porton Down Salisbury, SP4 0JG, UK	
Date of deposit 15 December 1995	Accession Number ECACC 95121524
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/> In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited biological material be made available only by issue thererof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions <i>mutatis mutandis</i> for any other designated state.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	
<input checked="" type="checkbox"/> This sheet was received with the international application	
Authorized officer 	
For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

23.

Applicant's or agent's file reference number	International application No.
--	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>6</u>, line <u>30</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution The European Collection of Animal Cell Cultures (ECACC)	
Address of depositary institution (including postal code and country) ECACC, CAMR Porton Down Salisbury, SP4 0JG, UK	
Date of deposit 15 December 1995	Accession Number ECACC 95121526
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited biological material be made available only by issue thererof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions <i>mutatis mutandis</i> for any other designated state.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., 'Accession Number of Deposit')	

For receiving Office use only

This sheet was received with the international application

Authorized officer
Diana Melling

For International Bureau use only

This sheet was received by the International Bureau on:

Authorized officer

24.

Applicant's or agent's file reference number	International application No.
--	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>6</u>, line <u>30</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution The European Collection of Animal Cell Cultures (ECACC)	
Address of depositary institution (including postal code and country) ECACC, CAMR Porton Down Salisbury, SP4 0JG, UK	
Date of deposit 15 December 1995	Accession Number ECACC 95121527
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited biological material be made available only by issue thererof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions <i>mutatis mutandis</i> for any other designated state.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., 'Accession Number of Deposit')	

For receiving Office use only

This sheet was received with the international application

Authorized officer

For International Bureau use only

This sheet was received by the International Bureau on:

Authorized officer

Ascre AB,
S-151 85 Sodertalje,
Sweden.

25
BUDAPEST TREATY IN THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITORY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR:	Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY:
M13 Phage B8	NCIMB 40779
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depository Authority accepts the microorganism identified under I above, which was received by it on 20 December ^(date of the original deposit) 1995	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depository Authority on ^(date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on ^(date of receipt of request for conversion)	
V. INTERNATIONAL DEPOSITORY AUTHORITY	
Name: Address: Name: NCIMB Ltd E3 St Machar Drive Aberdeen Scotland UK AB2 1RY	Signature(s) of person(s) having the power to represent the International Depository Authority or of authorized official(s): Date: <u>J. ...</u> 8 February 1996

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

26

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To Astra Aktiebolag
Patent Department
S-151 85 Sodertakje
Sweden

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITORY AUTHORITY
identified at the bottom of this page

NAME AND ADDRESS
OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the
DEPOSITOR:

5F8

Accession number given by the
INTERNATIONAL DEPOSITORY AUTHORITY:

95121524

II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

a scientific description

a proposed taxonomic designation

(Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depository Authority accepts the microorganism identified under I above,
which was received by it on 15/12/95 (date of the original deposit)¹

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International
Depository Authority on (date of the original deposit) and
a request to convert the original deposit to a deposit under the Budapest Treaty
was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITORY AUTHORITY

Name: Dr a Doyle

Signature(s) of person(s) having the power
to represent the International Depository
Authority or of authorized official(s):

Address: ECACC, CAMR,
Porton Down
Salisbury, SP4 0JG, UK

Date:

14.3.96

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To Astra Aktiebolag
Patent Department
S-151 85 Sodertakje
Sweden

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITORY AUTHORITY
identified at the bottom of this page

NAME AND ADDRESS
OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM		
Identification reference given by the DEPOSITOR:	Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY:	
2H6	95121526	
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION		
The microorganism identified under I above was accompanied by:		
<input checked="" type="checkbox"/> a scientific description		
<input type="checkbox"/> a proposed taxonomic designation		
(Mark with a cross where applicable)		
III. RECEIPT AND ACCEPTANCE		
This International Depository Authority accepts the microorganism identified under I above, which was received by it on 15/12/95 (date of the original deposit) ¹		
IV. RECEIPT OF REQUEST FOR CONVERSION		
The microorganism identified under I above was received by this International Depository Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)		
V. INTERNATIONAL DEPOSITORY AUTHORITY		
Name: Address:	Dr a Doyle ECACC, CAMR, Porton Down Salisbury, SP4 0JG, UK	Signature(s) of person(s) having the power to represent the International Depository Authority or of authorized official(s): Date: 14.3.96

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

TO Astra Aktiebolag
Patent Department
S-151 85 Sodertakje
Sweden

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITORY AUTHORITY
identified at the bottom of this page

NAME AND ADDRESS
OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the
DEPOSITOR:

5D8

Accession number given by the
INTERNATIONAL DEPOSITORY AUTHORITY:

95121527

II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

a scientific description

a proposed taxonomic designation

(Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depository Authority accepts the microorganism identified under I above,
which was received by it on 15/12/95 (date of the original deposit)¹

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International
Depository Authority on (date of the original deposit) and
a request to convert the original deposit to a deposit under the Budapest Treaty
was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITORY AUTHORITY

Name: Dr a Doyle

Signature(s) of person(s) having the power
to represent the International Depository
Authority or of authorized official(s):

Address: ECACC, CAMR,

Date:

Porton Down

14.3.96

Salisbury, SP4 0JG, UK

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

CLAIMS

1. A modified bacteriophage for use in the treatment or prophylaxis of a bacterial infection, which bacteriophage presents at its surface a recombinant protein comprising
 - (i) a first component derived from a bacteriophage surface protein; and
 - (ii) a second component comprising variable region sequences of an antibody to provide a bacterial antigen binding site, said second component rendering said bacteriophage capable of binding to and thereby inhibiting growth of bacterial cells involved in the etiology of said infection.
2. A bacteriophage as claimed in claim 1 for use in the treatment or prophylaxis of a mucosal bacterial infection.
3. A bacteriophage as claimed in claim 2 for use in the treatment or prophylaxis of *Helicobacter pylori* infection.
4. A bacteriophage as claimed in any one of claims 1 to 3 which is a modified filamentous bacteriophage.
5. A bacteriophage as claimed in any one of claims 1 to 4 which is a modified M13 bacteriophage.
6. A bacteriophage as claimed in any one of claims 1 to 5 wherein said first component of said recombinant protein is derived from the protein responsible for adsorption of the unmodified form of said bacteriophage to bacterial pili.
7. A bacteriophage as claimed in any one of claims 1 to 6 wherein said second component of said recombinant protein comprises a ScFv polypeptide.

8. A bacteriophage as claimed in any one of claims 1 to 7 which is a modified M13 bacteriophage wherein said first component of said recombinant protein is derived from the g3p protein.

5

9. A bacteriophage as claimed in claim 8 wherein said recombinant protein is a g3p - ScFv fusion protein.

10. A bacteriophage as claimed in any one of claims 1 to 9 for use in the treatment or prophylaxis of *Helicobacter pylori* infection wherein the antibody variable region sequences of said recombinant polypeptide are variable region sequences of a monoclonal antibody selected from the monoclonal antibodies of hybridoma cell lines 5F8 (ECACC No.95121524), 2H6 (ECACC No.95121526) and 5D8 (ECACC No.95121527).

15

11. The modified M13 bacteriophage of claim 10 designated B8 deposited at the NCIMB under accession number NCIMB 40779, or a derivative thereof which retains the ability to bind and infect *Helicobacter pylori*.

20 12. A pharmaceutical composition comprising a bacteriophage as claimed in any one of the preceding claims in admixture with a pharmaceutically acceptable carrier or excipient.

25 13. A method for treatment of a bacterial infection in a mammal which comprises administering a bacteriophage or pharmaceutical composition according to any one of the preceding claims.

30 14. Use of a bacteriophage as claimed in any one of claims 1 to 11 in the manufacture of a medicament for the treatment or prophylaxis of a mucosal bacterial infection.

15. A hybridoma selected from 5F8 (ECACC No.95121524), 2H6 (ECACC No.95121526) and 5D8 (ECACC No.95121527).
- 5 16. A monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas according to claim 15.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 97/00172

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 7/01, A61K 39/40, C07K 16/12 // C07K 19/00
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EDOC, MEDLINE, CA, BIOSIS, DBA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9201047 A1 (CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED), 23 January 1992 (23.01.92), see page 23, line 13-29, claims and the whole document --	1-16
X	WO 9516027 A1 (BIOINVENT INTERNATIONAL AB), 15 June 1995 (15.06.95), the whole document	1-11
A	-- -----	12-16

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
13 May 1997	25.05.1997

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer
 Patrick Andersson
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/04/97

International application No.

PCT/SE 97/00172

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9201047 A1	23/01/92	AT 145237 T		15/11/96
		AU 664155 B		09/11/95
		AU 8221691 A		04/02/92
		CA 2086936 A		11/01/92
		DE 69123156 D		00/00/00
		EP 0585287 A		09/03/94
		EP 0589877 A,B		06/04/94
		SE 0589877 T3		
		ES 2096655 T		16/03/97
		WO 9220791 A		26/11/92
		AU 665190 B		21/12/95
		AU 1693892 A		30/12/92
		CA 2109602 A		26/11/92
		JP 6508511 T		29/09/94
<hr/>		<hr/>		
WO 9516027 A1	15/06/95	AU 1252195 A		27/06/95
		EP 0739413 A		30/10/96
		SE 9304060 D		00/00/00
<hr/>				